Besponsa Approved for Pediatric Patients With Acute Lymphoblastic Leukemia
The FDA approved inotuzumab ozogamicin (Besponsa, Pfizer) for pediatric patients aged 1 year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL).